Prestige BioPharma

Prestige Biopharma Ltd. is a Singapore-based biopharmaceutical company specializing in the discovery and development of biosimilars, novel antibodies, and vaccines. The company has operations in the US and South Korea. Prestige Biopharma's product pipeline includes biosimilars in various stages of development, including HD201 trastuzumab (Tuzune) which is currently under EU EMA's marketing authorization application review. The company's robust pipeline also includes an innovative therapy for pancreatic cancer, PBP1510 (INN: Ulenistamab), which is in Phase 1/2a clinical trial in Europe. Other key products in development include HD204 (Vasforda), an Avastin biosimilar in global Phase 3 trials, and PBP1502, a Humira biosimilar in Phase 1 clinical trials in Europe.

Prestige Biopharma has developed proprietary bioprocessing technology that allows for expedited development programs while maintaining high quality and cost competitiveness. The company's manufacturing facility, Prestige Biologics, received European Union Good Manufacturing Practices (GMP) certification in February 2022. Prestige Biopharma has expanded its manufacturing capabilities significantly, with its EU-GMP certified facility expanding capacity up to 234,000 liters through second campus developments as of 2022.

In addition to biosimilars and novel antibodies, Prestige Biopharma's business includes alliance vaccine development and production. The company has been involved in the partnered commercial production of Covid-19 vaccines. Prestige Biopharma opened a global-scale vaccine manufacturing center in Osong, South Korea in December 2021, which began pilot production of the Sputnik V Covid-19 vaccine in August 2021.

Key customers and partnerships

In July 2022, Prestige Biopharma entered into an exclusive partnership with Intas Pharmaceuticals Limited for the commercialization of Prestige's bevacizumab biosimilar in key markets including the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, and several Southeast Asian countries. This collaboration leverages Intas' affiliate Accord healthcare's strong sales and marketing capabilities in successfully bringing new biosimilars to market. As of 2022, Accord supplied around one in three injectable oncology medicines in Europe.